39263-34-8

Basic information

• Product Name: N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE
• Synonyms: N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE;(E)-N'-(2-cyano-4-nitrophenyl)-N,N-diMethylforMiMidaMide
• CAS NO: 39263-34-8
• Molecular Formula: C₁₀H₁₀N₄O₂
• Molecular Weight: 218.212
• Mol File: 39263-34-8.mol
• Article Data: 4

Chemical Properties

• Melting Point: 146-148
• Boiling Point: 387.7 °C at 760 mmHg
• Flash Point: 188.3 °C
• Appearance: /
• Density: 1.2 g/cm³
• CAS DataBase Reference: N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE(39263-34-8)
• EPA Substance Registry System: N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE(39263-34-8)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 39263-34-8(Hazardous Substances Data)

Usage

General Description

N'-(2-cyano-4-nitrophenyl)-N,N-dimethyliminoformamide is a chemical compound with the structural formula C??H?N?O?. It is a yellow crystalline solid that is used as a reagent in organic synthesis and as an intermediate in the production of pharmaceuticals and agrochemicals. The compound has potential mutagenic and irritant properties and should be handled with care. It is an iminoformamide derivative and is commonly used in laboratories for its versatile reactivity in the synthesis of various organic compounds. The compound is also known by its CAS number 37238-57-8 and is subject to regulations regarding its handling, transportation, and storage due to its potential hazards.

Upstream product

• 17420-30-3 5-nitroanthranilonitrile 
• 68-12-2 N,N-dimethyl-formamide 
• 91-56-5 indole-2,3-dione 
• 49675-77-6 3-(hydroxyimino)-5-nitroindolin-2-one 
• 100-01-6 4-nitro-aniline 
• 611-09-6 5-nitroisatin 
• 17122-62-2 hydroxyimino-acetic acid-(4-nitro-anilide) 

Downstream Products

• 1333163-07-7 (E)-N-(4-(3-bromophenylamino)quinazolin-6-yl)-3-(3-methoxyphenyl)acrylamide 
• 1333163-08-8 (E)-N-(4-(3-bromophenylamino)quinazolin-6-yl)-3-(thiophen-2-yl)acrylamide 
• 1333163-09-9 (E)-N-(4-(3-bromophenylamino)quinazolin-6-yl)-3-(p-tolyl)acrylamide 
• 1333163-10-2 (E)-N-(4-(3-bromophenylamino)quinazolin-6-yl)-3-(4-nitrophenyl)acrylamide 
• 1333163-14-6 (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(2-chlorophenyl)acrylamide 
• 1333163-15-7 (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(4-bromophenyl)acrylamide 
• 1333163-16-8 (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(2-bromophenyl)acrylamide 
• 1333163-17-9 (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(3-methoxyphenyl)acrylamide 
• 1333163-18-0 (E)-N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3-(thiophen-2-yl)acrylamide 
• 1333163-19-1 (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-p-tolylacrylamide 
• 1333163-20-4 (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(naphthalen-4-yl)acrylamide 
• 1333163-21-5 (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(4-nitrophenyl)acrylamide 
• 1333163-22-6 (E)-N-(4-(3-chlorophenylamino)quinazolin-6-yl)-3-(2-nitrophenyl)acrylamide 
• 1333163-00-0 (E)-N-(4-(3-bromophenylamino)quinazolin-6-yl)cinnamamide 

Relevant articles and documents

Large yellow acid anilinoquinazoline derivatives preparation and anti-tumor application

The invention discloses large yellow acid anilinoquinazoline derivatives preparation and for anti-tumor. In order to parietic acid as a lead compound, is introduced into the 4 - anilinoquinazoline structure, synthesis is contained and 1, 8 - [...] - 9, 10 - anthraquinone - N - (6 - amino - 4 - anilinoquinazoline) - 3 - carboxamides of the compound. Cell test Certificate, the class of compounds of the nasopharyngeal carcinoma cells, breast cancer cells, liver cancer cells and ovarian cancer cells with different degree suppression effect, can be used for anti-tumor pharmaceutical preparation.

Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors

Series of 4-anilinoquinazoline derivatives were conveniently and efficiently synthesized and their antitumor activities were evaluated by MTT assay in three human cancer cell lines: H1975, HepG2 and SMMC-7721. New compounds 19a-19h were designed and synthesized to seek for powerful EGFR inhibitors and to explore whether methyl group at C-2 position of quinazoline ring has a positive effect on EGFR inhibition. All the compounds of 19a-19h were found potent against all three cell lines and five compounds (19c, 19d, and 19f-19h) were found more potent against H1975 than gefitinib. SAR studies revealed that methyl group at C-2 position of quinazoline ring could significantly improve the antitumor potency of 4-anilinoquinazolines. The same conclusion was also drawn according to the results of Western blotting analysis. Among all the tested compounds, 19g exhibited extremely potent against H1975 with an IC50 value of 0.11 μM, remarkably lower than that of gefitinib (1.23 μM). The results of western blotting analysis showed that compounds 19c and 19g could notably inhibit the expression of phosphorylated EGFR, especially 19g, almost inhibited completely.